Biodexa Pharmaceuticals PLC
BDRX5.650USD
-0.055-0.97%
Handelsschluss 09/05, 16:00（ET）Kurse um 15 Minuten verzögert
37.78BMarktkapitalisierung
--KGV TTM
mehr Informationen über Biodexa Pharmaceuticals PLC Unternehmen
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Unternehmensinformationen
BörsenkürzelBDRX
Name des UnternehmensBiodexa Pharmaceuticals PLC
IPO-datumDec 08, 2014
CEOMr. Stephen A. Stamp
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeDec 08
Addresse1 Caspian Point
StadtABINGDON
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlCF10 4DQ
Telefon4401235888300
Websitehttps://www.biodexapharma.com/
BörsenkürzelBDRX
IPO-datumDec 08, 2014
CEOMr. Stephen A. Stamp
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sijmen De Vries, M.D.
Dr. Sijmen De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sijmen De Vries, M.D.
Dr. Sijmen De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Währung: GBPAktualisiert: Sun, Jul 6
Währung: GBPAktualisiert: Sun, Jul 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionGBP
Name
Umsatz
Anteil
Belgium
381.00K
100.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jul 11
Aktualisiert: Fri, Jul 11
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
2.83%
2.71%
0.39%
0.23%
0.23%
Andere
93.61%
Aktionäre
Aktionäre
Anteil
2.83%
2.71%
0.39%
0.23%
0.23%
Andere
93.61%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
5.73%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.23%
Research Firm
0.09%
Venture Capital
0.09%
Hedge Fund
0.08%
Bank and Trust
0.03%
Andere
92.80%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
36
46.40K
7.49%
+35.30K
2025Q1
38
272.70K
5.41%
+162.94K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
2023Q1
22
183.00
8.18%
-2.20K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
175.24K
3.47%
+175.24K
--
May 20, 2025
167.68K
3.32%
+110.57K
+193.59%
Nov 14, 2024
24.34K
0.48%
+24.34K
--
Jul 19, 2024
14.18K
0.28%
+14.18K
--
Apr 01, 2024
14.18K
0.28%
+14.18K
--
Apr 01, 2024
14.18K
0.28%
+7.93K
+126.83%
Apr 01, 2024
1.43K
0.03%
+1.43K
--
Mar 31, 2025
6.31K
0.12%
+6.31K
--
Apr 01, 2024
1.00
0%
--
--
Mar 31, 2025
5.42K
0.11%
+5.33K
+5923.33%
Dec 31, 2023
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Datum
Art
Verhältnis
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
Mar 16, 2023
Merger
4→1
Mehr Anzeigen
